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Usefulness of dynamic risk stratification in pediatric 
patients with differentiated thyroid carcinoma 
Kwangsoon Kim, Won Woong Kim, Jung Bum Choi, Min Jhi Kim, Cho Rok Lee, Jandee Lee, Sang-Wook Kang, 
Kee-Hyun Nam, Woong Youn Chung, Jong Ju Jeong
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
INTRODUCTION
The incidence and prevalence of differentiated thyroid 
carcinoma (DTC) have been rising significantly over the last 2 
decades [1-3]. DTC is the most common endocrine carcinoma 
in pediatric patients and accounts for 2%–10% of all pediatric 
carcinomas [4-6]. The distinctive feature of DTC in pediatric 
patients is its aggressiveness, with more lymph node (LN) 
metastasis, distant metastasis, and extrathyroidal extension 
(ETE) [7-11]. At the same time, the mortality rate in pediatric 
patients is extremely low [12-15]. 
The American Joint Committee on Cancer (AJCC)/Union for 
International Cancer Control (UICC) TNM staging system is 
widely used for predicting the prognosis of DTC [16]. However, 
the AJCC/UICC TNM staging system has a limitation with 
regard to the assessment of DTC in pediatric patients. Unlike 
with adults, the disease in pediatric patients is classified into 
only 2 stages due to the age cutoff: stage I without distant 
metastasis and stage II with distant metastasis. 
In the American Thyroid Association (ATA) guidelines newly Reviewed 
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Purpose: Recently, the American Thyroid Association (ATA) dynamic risk stratification (DRS) has been verified to be 
more valuable than the static anatomical staging system for predicting prognosis in patients with differentiated thyroid 
carcinoma (DTC). The purpose of this retrospective study was to compare the clinical usefulness of DRS, which is based on 
the response to initial treatment, with that of ATA initial risk stratification in pediatric patients.
Methods: A total of 144 pediatric patients underwent thyroid operation from August 1982 to December 2013 at Yonsei 
University Hospital (Seoul, Korea). Among them, 128 patients with complete clinical data were enrolled in this study. 
Clinicopathologic features and surgical outcomes were retrospectively analyzed by medical chart review. The mean follow-
up duration was 11.5 years.
Results: The mean tumor size was 2.1 cm; 80.4% of patients were diagnosed with conventional papillary thyroid carcinoma, 
and 7.0% of patients were diagnosed with follicular thyroid carcinoma. Low-risk patients had the highest probability of an 
excellent response to initial treatment (66.6%). High-risk patients had the highest probability of a structural incomplete 
response (100%) and the lowest probability of an excellent response (11.1%). The ATA risk stratification and the DRS 
system were independent risk factors for disease-free survival (DFS) (P = 0.041 and P < 0.001, respectively).
Conclusion: The DRS system, which is based on the response to initial treatment, can offer more useful prognostic 
information compared with ATA risk stratification in pediatric patients with DTC.
[Ann Surg Treat Res 2018;95(4):222-229]
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released in 2015, pediatric patients with DTC were reclassified 
into 3 groups: low, intermediate, and high risk according 
to extent of tumor and nodal status [17]. However, this risk 
stratification system is still inadequate for predicting accurate 
prognoses in pediatric patients. 
A previous study suggested a dynamic risk stratification (DRS) 
system that was based on response to initial treatment [18]. 
Patients with DTC were restratified according to suppressed and 
stimulated thyroglobulin (Tg) levels, Tg antibody (TgAb) level, 
and imaging modalities, including neck ultrasonography and 
whole body scan (WBS) during follow-up. This study reported 
that the DRS system provided more accurate prognostic 
information. However, to the best of our knowledge, there have 
been few studies investigating the use of the DRS system for 
pediatric patients with DTC.
The purpose of this study was to identify the clinical value 
of the ATA risk stratification system in pediatric patients with 
DTC. We also compared the clinical usefulness of the DRS 
system with that of ATA initial risk stratification.
METHODS
Patients
A total of 144 pediatric patients with DTC who had 
undergone thyroid operations from August 1982 to December 
2013 were retrospectively reviewed at Yonsei University 
Hospital (Seoul, Korea). Sixteen patients were excluded because 
they had inadequate follow-up data; thus, 128 patients were 
analyzed by complete review of medical charts and pathology 
reports. Among them, 40 (31.2%) had undergone bilateral total 
thyroidectomy (BTT), and 43 (33.6%) had undergone BTT with 
therapeutic modified radical neck dissection (mRND). These 
patients received subsequent radioactive iodine (RAI) ablation. 
The mean follow-up duration was 11.5 years (range, 2.1–29.8 
years). This study was approved by the at Yonsei University 
Hospital Institutional Review Board (4-2015-1160).
Postoperative management and follow-up
The management protocol followed the ATA management 
guidelines [17]. Tg and TgAb concentrations were regularly 
measured, and physical examinations, neck ultrasonography 
and thyroid function tests were performed at 3 and 6 months 
and annually thereafter. Postoperative RAI treatment was 
performed 4 to 6 weeks after operation, and WBSs were 
performed 5 to 7 days after RAI ablation. All patients were 
prescribed a suppressive dose of L-thyroxine (thyroid-
stimulating hormone [TSH] < 0.05 mIU/L). Patients who had 
clinical suspicion of recurrence of disease or distant metastasis 
were evaluated by additional diagnostic imaging, including 
computed tomography, positron emission tomography/
computed tomography, and/or RAI WBS. To confirm the 
recurrence of disease, ultrasound-guided fine needle aspiration 
biopsy was performed in addition to imaging modalities.
Definition of ATA risk stratification
The 2015 ATA risk stratification system for pediatric patients 
was applied to the study subjects, dividing them into low, 
intermediate, and high-risk groups [17]. The low-risk group was 
defined as pediatric patients with DTC grossly confined to the 
thyroid (AJCC/UICC TNM staging system T1 to T3) with clinical 
N0/Nx disease or with pathologic N1a micrometastases (number 
of LNs ≤ 5 and largest dimension of metastatic foci < 0.2 cm). 
The intermediate-risk group was defined as pediatric patients 
with DTC accompanied with pathologic N1a metastases (number 
of LNs > 5 or largest dimension of metastatic foci ≥ 0.2 cm) 
or minimal N1b metastases (number of LNs ≤ 10 and largest 
dimension of metastatic foci < 3 cm). The high-risk group 
was defined as pediatric patients with DTC with pathologic 
N1b metastases (number of LNs > 10 or largest dimension of 
metastatic foci ≥ 3 cm), locally invasive disease (T4), or distant 
metastasis.
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Table 1. Definition of dynamic risk stratification based on response to the initial treatment
Response Total thyroidectomy with RAI ablation Lobectomy alone
Excellent response Negative imaging and suppressed Tg < 0.2 ng/mL 
or stimulated Tg < 1 ng/mL, undetectable TgAb
Negative imaging and stable nonstimulating Tg < 
30 ng/mL
Indeterminate response Nonspecific imaging findings and
suppressed Tg detectable, but < 1 ng/mL or 
stimulated Tg detectable, but < 10 ng/mL or TgAb 
stable or declining 
Nonspecific imaging findings and TgAb stable or 
declining
Biochemical incomplete 
response
Negative imaging and suppressed Tg ≥ 1 ng/mL or 
stimulated Tg ≥ 10 ng/mL or TgAb rising 
Negative imaging and nonstimulated Tg > 30 ng/mL 
or increasing Tg levels with similar TSH levels or 
TgAb rising
Structural incomplete 
response
Structural or functional evidence of disease 
regardless of Tg or TgAb levels
Structural or functional evidence of disease 
regardless of Tg or TgAb
RAI, radioactive iodine; TgAb, Tg antibody; TSH, thyroid-stimulating hormone.
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Definition of DRS
The DRS system classified pediatric patients into 4 groups, as 
shown in previous studies: excellent response, indeterminate 
response, biochemical incomplete response, and structural 
incomplete response [18-21]. The best response to the initial 
treatment was evaluated between 1 and 2 years after diagnosis 
of DTC with Tg level, TgAb level, and imaging findings. The 
definition of DRS classification according to the extent of 
surgery is shown in Table 1. 
Definition of clinical outcomes
Patients with negative stimulated Tg, negative TgAb, 
and no evidence of structural disease at the final follow-
up were defined as having no evidence of disease (NED). 
Biochemical-persistent disease in patients who underwent 
total thyroidectomy with RAI ablation was defined as negative 
imaging findings with suppressed Tg > 1 ng/mL or increasing 
TgAb level; in patients who underwent lobectomy, this was 
defined as negative imaging findings with nonstimulated Tg 
> 30 ng/mL or increasing Tg level with similar TSH level or 
increasing TgAb. Structural persistent/recurrent disease was 
defined as pathologically or cytologically verified malignancy 
and/or metastasis by imaging modalities regardless of Tg or 
TgAb level [20].
Statistical analysis
Continuous, quantitative variables are provided as mean 
with standard deviation. Categorical and qualitative variables 
are reported as number with percentage. Multivariate Cox 
regression analysis was performed to identify the independent 
risk factors of DFS. DFS was compared by Kaplan-Meier analysis 
with log-rank test between groups. The proportion of variance 
explained (PVE) value was calculated with the Cox regression 
model, using the following equation:
PVE = 1 – exp(-G2/n)
where G2 is the maximum likelihood ratio from the Cox 
regression model, and n is the total number of patients [22]. 
Hazard ratios (HRs) with 95% confidence intervals (CIs) were 
calculated, and 2-sided P-values of <0.05 were regarded as 
statistically significant. All statistical analyses were performed 
using R package version 3.1.3 (http://www.R-project.org).
RESULTS
Baseline clinicopathologic characteristics of 
pediatric patients with DTC 
Table 2 provides the baseline clinicopathologic characteristics 
of the 128 pediatric patients with DTC. The mean age of study 
patients was 16.5 years (range, 4–19 years); among them, 9 
(7.0%) were younger than 10 years. A total of 114 patients (89.1%) 
were female, and the mean tumor size was 2.1 cm (range, 
0.2–6.0 cm). A total of 103 patients (80.5%) were diagnosed with 
conventional papillary thyroid carcinoma (PTC), and 9 patients 
(7.0%) were diagnosed with follicular thyroid carcinoma (FTC). 
The remaining patients (12.5%) were diagnosed with other types 
of PTC. Multiplicity and bilaterality of carcinoma were found 
in 36 (28.1%) and 26 patients (20.3%), respectively. Seventy-
six patients (59.4%) were identified with ETE. Forty patients 
(31.2%) underwent BTT, and 43 patients (33.6%) underwent 
BTT with therapeutic mRND due to N1b nodes. The numbers 
of patients with T1, T2, T3, and T4a were 29 (22.7%), 19 (14.8%), 
74 (57.8%), and 6 (4.7%), respectively. Forty-six patients (35.9%) 
Table 2. Baseline clinicopathologic characteristics of the 
study patients (n = 128)
Characteristic Value
Age (yr) 16.5 ± 3.0 (4–19)
 ≤10 9 (7.0)
 >10, <15 25 (19.5)
 ≥15, <20 94 (73.4)
Sex, male:female 1:8.1 (14:114)
Tumor size (cm) 2.1 ± 1.3 (0.2–6.0)
Type of carcinoma
Conventional PTC 103 (80.5)
Diffuse sclerosing PTC 10 (7.8)
Follicular variant PTC 5 (3.9)
Wartin variant PTC 1 (0.8)
FTC 9 (7.0)
Multiplicity 36 (28.1)
Bilaterality 26 (20.3)
Extrathyroidal extension 76 (59.4)
Surgery
Less than TT 45 (35.2)
Bilateral TT 40 (31.2)
Bilateral TT + mRND 43 (33.6)
T stage
T1 29 (22.7)
T2 19 (14.8)
T3 74 (57.8)
T4a 6 (4.7)
N stage
N0 39 (30.5)
N1a 46 (35.9)
N1b 43 (33.6)
M stage
M1 6 (4.7)
recurrence
Loco-regional 18 (14.1)
Distant 5 (3.9)
Follow-up duration (yr) 11.5 ± 5.9 (2.1–29.8)
Values are presented as mean ± standard deviation (range) or 
number (%).
PTC, papillary thyroid carcinoma; FTC, follicular thyroid 
carcinoma; TT, total thyroidectomy; mRND, modified radical 
neck dissection.
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had cervical LN metastasis, and 43 patients (33.6%) had lateral 
LN metastasis. Only 6 patients (4.7%) were diagnosed as having 
distal metastasis of the lung at the same time as diagnosis of 
thyroid carcinoma. Loco-regional recurrence was detected in 
18 patients (14.1 %), and recurrence with distant metastasis to 
the lung was detected in 5 patients (3.9%). The mean follow-up 
duration was 11.5 years (range, 2.1–29.8 years). 
Clinical outcomes with ATA risk stratification
Using the ATA risk stratification system, 62 patients (48.4%) 
were classified into the low-risk group, 38 patients (29.7%) were 
classified into the intermediate-risk group, and 28 patients 
(21.9%) were classified into the high-risk group. Table 3 shows 
the clinical outcomes according to the ATA risk stratification 
system. Most of the patients (87.1%) in the low-risk group 
had NED, and only 1 patient (1.6%) was diagnosed with 
structural persistent/recurrent disease. On the other hand, 8 
patients (28.6%) in the high-risk group were diagnosed with 
structural persistent/recurrent disease. The DFS of the ATA risk 
stratification system were significantly different (P = 0.041) (Fig. 
1).
Clinical outcomes with DRS
Using the DRS system, the patients were reclassified into 4 
groups: excellent response, 63 (49.2%); indeterminate response, 
37 (28.9%); biochemical incomplete response, 18 (14.1%); and 
structural incomplete response, 10 (7.8%). Table 4 presents 
the clinical outcomes according to the DRS system. Sixty-one 
patients (96.8%) in the excellent response group had NED, and 
only 2 patients (3.2%) had biochemical persistent disease. The 
majority of patients (78.4%) in the indeterminate group had 
NED, while 7 patients (18.9%) and 1 patient (2.7%) were verified 
as having biochemical persistent and structural persistent/
recurrent disease, respectively. On the other hand, slightly more 
than half of the patients (55.6%) in the biochemical incomplete 
group were diagnosed with biochemical persistent disease, and 
4 patients (22.2 %) were diagnosed with structural persistent/
recurrent disease. Eight patients (80%) in the structural 
incomplete response group were diagnosed with structural 
Kwangsoon Kim, et al: Dynamic risk stratification in pediatric patients
Table 3. Clinical outcomes with ATA risk stratification system
Variable Low (n = 62) Intermediate (n = 38) High (n = 28)
Death (n = 0) 0 (0) 0 (0) 0 (0)
NED (n = 95) 54 (87.1) 25 (65.8) 16 (57.1)
Biochemical persistent (n = 20) 7 (11.3) 9 (23.7) 4 (14.3)
Structural persistent/recurrence (n = 13) 1 (1.6) 4 (10.5) 8 (28.6)
Values are presented as number (%).
ATA, American Thyroid Association; NED, no evidence of disease.
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Fig. 1. Disease-free survival curves according to American 
Thyroid Association risk stratification system (P = 0.041).
Table 4. Clinical outcomes with response to initial therapy (DRS) system (n = 128)
Variable Excellent  (n = 63)
Indeterminate 
 (n = 37)
Biochemical 
incomplete  
(n = 18)
Structural 
incomplete (n = 10)
Death (n = 0) 0 (0) 0 (0) 0 (0) 0 (0)
NED (n = 95) 61 (96.8) 29 (78.4) 4 (22.2) 1 (10.0)
Biochemical persistent (n = 20) 2 (3.2) 7 (18.9) 10 (55.6) 1 (10.0)
Structural persistent/recurrence (n = 13) 0 (0) 1 (2.7) 4 (22.2) 8 (80.0)
Values are presented as number (%).
DRS, dynamic risk stratification; NED, no evidence of disease.
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persistent/recurrent disease, and only 1 patient (10%) had 
NED. The Kaplan-Meier survival analysis showed statistically 
significant differences among the response groups with the 
DRS system (P < 0.001) (Fig. 2).
Correlation and comparison of predictive accuracy 
between ATA risk stratification and DRS
The correlation between the ATA risk stratification system 
and the DRS system is shown in Table 5. Of the patients 
who had excellent responses at initial evaluation after initial 
therapy, 42 (66.6%) were in the low-risk group, while 7 (11.1%) 
were in the high-risk group. Twelve patients (66.6%) with 
biochemical incomplete response were in the intermediate-
risk group, and all patients with structural incomplete response 
were in the high-risk group. 
To compare the predictive accuracy of prognosis between the 
ATA risk stratification system and the DRS system, the PVE was 
calculated. The PVE value of the DRS system was 54.9%, which 
was higher than that of the ATA risk stratification system, 
29.8%.
Risk analysis for DFS with 2 risk stratification system
To determine the independent risk factors associated with 
DFS, a multivariate analysis was performed (Table 6). Tumor 
size over 1 cm (HR, 15.130; 95% CI, 0.997–197.19; P = 0.016) 
and N1b stage (HR, 7.914; 95% CI, 5.192–9.683; P = 0.001) 
were confirmed as significant predictors for recurrence. In 
the ATA risk stratification system, the risk of recurrence was 
significantly higher in the high-risk group (HR, 9.371; 95% CI, 
0.283–450.487; P = 0.045) than in the low-risk group. The 
risk of recurrence in the DRS system was significantly higher 
in all other groups than in the excellent response group: 
indeterminate group (HR, 6.104; 95% CI, 1.258–29.613; P = 
0.025), biochemical incomplete group (HR, 7.562; 95% CI, 1.131–
50.539; P = 0.037), and structural incomplete group (HR, 44.487; 
95% CI, 3.343–592.01; P = 0.004).
DISCUSSION
The ATA risk stratification system released in 2015 is 
regarded as an appropriate method for prediction of recurrent 
or persistent disease after initial treatment in pediatric 
patients with DTC [17]. In the ATA system, pediatric patients 
are classified into 3 risk groups. However, several studies have 
reported that the ATA risk stratification system is inappropriate 
to predict prognosis in pediatric patients with DTC [19,23]. The 
present study was designed to compare the clinical usefulness 
of the ATA risk stratification system with that of the DRS 
system, which is based on the initial treatment response as 
measured by serum Tg and TgAb levels and imaging findings. 
Serum Tg level is used as a tumor marker for patients with DTC 
after BTT. However, false-negative results could result from 
TgAb interference with Tg measurements [24]. 
The clinical features of DTC are different between pediatric 
and adult patients. LN metastasis occurs in 60% to 80% of 
pediatric patients with DTC, and lung metastasis occurs in 
10% to 20% [25]. In our study, 89 (69.5%) and 6 patients (4.7%) 
were diagnosed as having LN and lung metastasis, respectively. 
However, in spite of aggressive disease, pediatric patients 
with DTC have a lower mortality rate than adult patients. 
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Fig. 2. Disease-free survival curves according to dynamic risk 
stratification system (P < 0.001).
Table 5. Correlation between ATA risk stratification and dynamic risk stratification system
Variable
ATA risk stratification
Low (n = 62) Intermediate (n = 38) High (n = 28)
Excellent response (n = 63) 42 (66.8) 14 (36.8) 7 (25.0)
Indeterminate response (n = 37) 17 (27.4) 12 (31.6) 8 (28.6)
Biochemical incomplete response (n = 18) 3 (4.8) 12 (31.6) 3 (10.7)
Structural incomplete response (n = 10) 0 (0) 0 (0) 10 (35.7)
Values are presented as number (%).
ATA, American Thyroid Association.
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Even though the evidence for the reasons for this difference is 
unclear, long-term prognosis of pediatric patients is excellent 
[26,27].
We recategorized pediatric patients into 4 groups according 
to response to initial treatment: excellent, indeterminate, 
biochemical incomplete, and structural incomplete. During 
the follow-up period, 42 patients (66.8%) in the low-risk group 
were recategorized into the excellent response group, and 
7 patients (25.0%) in the high-risk group were recategorized 
into the excellent response group. Of the patients in the 
excellent response group, 96.8% had NED, but only 2 (3.2%) 
were diagnosed with structural persistent/recurrent disease. 
Twelve of the 38 patients (31.6%) in the intermediate-risk group 
were reclassified into the biochemical incomplete response 
group. The number of patients reclassified according to the 
DRS system was significant considering the possibility (77.8%) 
of biochemical persistent or structural persistent/recurrent 
disease. In the high-risk group, 10 patients (35.7%) were 
reclassified into the structural incomplete response group, 
and 90% of the patients in the structural incomplete response 
group were diagnosed as having biochemical persistent or 
structural persistent/recurrent disease. The DRS system could 
provide a wider variety of information about patient disease 
status in order to modify the management strategy or to better 
determine the treatment plan for pediatric patients with DTC.
The ATA guidelines recommend total thyroidectomy for 
pediatric patients with DTC, because they have an increased 
incidence of bilateral and multifocal disease [17]. Total 
thyroidectomy could guarantee RAI ablation and the use of Tg 
as a tumor marker. Eighty-three patients (64.8%) underwent 
total thyroidectomy in this present study. However, 45 patients 
(35.2%) underwent unilateral thyroidectomy due to limited 
disease in the unilateral thyroid. 
In the multivariate analysis, the results showed that the 
high-risk group had a significantly higher risk of recurrence 
compared with the low-risk group (P = 0.045), but the 
intermediate-risk group was similar to the low-risk group (P = 
0.954) according to the ATA risk stratification system. On the 
other hand, the indeterminate, biochemical incomplete, and 
structural incomplete response groups were at significantly 
higher risk of recurrence compared with the excellent group (P 
= 0.025, P = 0.037, and P = 0.004, respectively) according to 
the DRS system. According to this analysis, we can infer that 
the DRS system is more useful to predict recurrence in pediatric 
patients with DTC. Similar to previous studies, our results 
also showed that tumor size (>1 cm) and N stage (N1b) were 
predictors for recurrence [28,29]. 
In addition, considering the PVE value, the DRS system 
has a clinical benefit for more precise predictability of DFS 
in pediatric patients with DTC. The results of this research 
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Table 6. Risk analysis for disease-free survival with 2 risk stratification systems
Variable HR (95% CI) P-value
Sex 1.098 (0.084–14.697) 0.943
Size (cm)
≤1 Reference -
>1 15.130 (0.997–197.19) 0.016
ETE 1.264 (0.375–4.257) 0.706
No. of lesions
Solitary Reference -
Multiplicity 1.922 (0.682–3.248) 0.936
Bilaterality 3.753 (0.978–12.497) 0.932
N stage
N0 Reference -
N1a 2.780 (1.906–2.971) 0.083
N1b 7.914 (5.192–9.683) 0.001
ATA risk stratification
Low Reference -
Intermediate 3.013 (0.750–121.370) 0.954
High 9.371 (0.283–450.487) 0.045
Dynamic risk stratification
Excellent Reference -
Indeterminate 6.104 (1.258–29.613) 0.025
Biochemical incomplete 7.562 (1.131–50.539) 0.037
Structural incomplete 44.487 (3.343–592.01) 0.004
HR, hazard ratio; CI, confidence interval; ETE, extrathyroidal extension; ATA, American Thyroid Association.
A statistically significant difference was defined as P < 0.05.
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support the idea that the DRS system is more useful for 
predicting persistent/recurrent disease compared with the ATA 
risk stratification system in pediatric patients with DTC. 
Several studies have been performed to investigate the 
accuracy with which systems predict prognosis in pediatric 
patients with DTC [6,15,19,23,30]. Lazar et al. [23] reported that 
their scoring system based on response to initial treatment was 
suitable for predicting the risk of persistent/recurrent disease 
in pediatric patients with DTC. Zanella et al. [30] found that 
postoperative stimulated Tg had high accuracy for prediction 
of persistent disease in pediatric patients with DTC. However, 
prognostic factors of pediatric patients with DTC are still 
controversial.
There are several limitations in the present study. Firstly, 
this study was retrospective in nature. Secondly, the study 
population included only 128 pediatric patients, which was a 
relatively small number of patients, and had a relatively short 
follow-up period (11.5 ± 5.9 years). Thirdly, there might have 
been selection bias as all patients were from a single tertiary 
institution. Finally, the mean age was 16.5 years (range, 4–19 
years): 94 patients (73.5%) were older than 15 years, and only 9 
patients (7.0%) were younger than 10 years.
The most important strength of this study is that all 
patients in our study were followed up with the same protocol, 
including type of surgery, RAI ablation protocol, degree of TSH 
suppression, and use of imaging modalities.
In conclusion, the DRS system is likely to enhance the 
predictability of prognosis with ATA risk stratification in 
pediatric patients with DTC. Further studies are required to 
determine whether DRS with adjusted response to the initial 
therapy regimen is useful in clinical practice.
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